

Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

Frontiers in Digestive Research and Practice

Name	Tae-Yong Kim
Affiliation	Seoul National University Hospital
Country	Republic of Korea
Major Field	Medical Oncology

Educational Background

1996 ~ 2000 Seoul National University, College of Medicine

Professional Experience

2009.3-2011.11 Assistant Professor, Seoul National University Boramae Hospital

2011.12-2016.3 Assistant Professor, Division of Hematology and Medical Oncology, Department of internal medicine, Seoul National University Hospital

2018.11-2019.10 Visiting Professor, Korea Advanced Institute of Science and Technology, Graduate School of Medical Science and Engineering, Laboratory of Immunology & Infectious Disease

2016.3-current Associate Professor, Division of Hematology and Medical Oncology, Department of internal medicine, Seoul National University Hospital

Main Scientific Publications

1. Kim TY, Kim SY, Kim JH, Jung HA, Choi YJ, Hwang IG, Cha Y, Lee GW, Lee YG, Kim TM, Lee SH, Lee S, Yun H, Choi YL, Yoon S, Han SW, Kim TY, Kim TW, Zang DY, Kang JH. Nationwide precision oncology pilot study: KOREAN Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05, ESMO Open. 2024 Oct;9(10):103709.
2. Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, Fazio N, Kim TY, Bai LY, Moran D, Yang J, Arozullah A, Park JW, Raizer JJ, Bang YJ, Shah MA. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma Clin Cancer Res. 2023 Oct 2;29(19):3882-3891.
3. Kwak Y, Kim TY, Nam SK, Hwang HJ, Han D, Oh HJ, Kong SH, Park DJ, Oh DY, Lee HJ, Im SA, Yang HK, Lee HS. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. Oncologist. 2025 Feb 6;30(2):oyae238.
4. Kim TY, Kwak Y, Nam SK, Han D, Oh DY, Im SA, Lee HS. Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer. ESMO Open. 2024 Dec;9(12):104000.